The hemagglutinin stem-binding monoclonal antibody VIS410 controls influenza virus-induced acute respiratory distress syndrome

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 4, 2016, Pages 2118-2131

  Baranovich, Tatiana ^a,c,d   Jones, Jeremy C ^a   Russier, Marion ^a   Vogel, Peter ^a   Szretter, Kristy J ^b   Sloan, Susan E ^b   Seiler, Patrick ^a   Trevejo, Jose M ^b   Webby, Richard J ^a   Govorkova, Elena A ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b VISTERRA INC   (United States)

^c NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^d Carter Consulting Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; ADAMANTANE; HUMAN MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY VIS410; PERAMIVIR; UNCLASSIFIED DRUG; ZANAMIVIR; HEMAGGLUTININ, HUMAN INFLUENZA A VIRUS; INFLUENZA VIRUS HEMAGGLUTININ; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG TARGETING; IC50; INFECTION PREVENTION; INFLUENZA A VIRUS (H7N9); INJURY SCALE; LUNG FUNCTION; LUNG INJURY SCORE; LUNG LAVAGE; MOUSE; NONHUMAN; PARAINFLUENZA VIRUS INFECTION; PRIORITY JOURNAL; RESPIRATORY DISTRESS SYNDROME; VIRAL CLEARANCE; ANIMAL; BAGG ALBINO MOUSE; BRONCHOALVEOLAR LAVAGE FLUID; CAPILLARY PERMEABILITY; CHEMISTRY; COMPLICATION; DISEASE MODEL; DOG; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; HUMAN; IMMUNOLOGY; LUNG; MDCK CELL LINE; MORTALITY; ORTHOMYXOVIRIDAE INFECTIONS; RESPIRATORY DISTRESS SYNDROME, ADULT; SERODIAGNOSIS; SURVIVAL ANALYSIS; VIROLOGY; VIRUS LOAD;

ANIMALS; ANTIBODIES, MONOCLONAL; BRONCHOALVEOLAR LAVAGE FLUID; CAPILLARY PERMEABILITY; DISEASE MODELS, ANIMAL; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS, H7N9 SUBTYPE; LUNG; MADIN DARBY CANINE KIDNEY CELLS; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; ORTHOMYXOVIRIDAE INFECTIONS; RESPIRATORY DISTRESS SYNDROME, ADULT; SURVIVAL ANALYSIS; VIRAL LOAD;

EID: 84963773526     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02457-15     Document Type: Article

References (51)

1. WHO. 2008. Immunization, vaccines, and biologicals: influenza. World Health Organization, Geneva, Switzerland. http://www.who.int./immunization/topics/influenza/en.
2. Gao R, Cao B, Hu Y, Feng Z, Wang D, Hu W, Chen J, Jie Z, Qiu H, Xu K, Xu X, Lu H, Zhu W, Gao Z, Xiang N, Shen Y, He Z, Gu Y, Zhang Z, Yang Y, Zhao X, Zhou L, Li X, Zou S, Zhang Y, Li X, Yang L, Guo J, Dong J, Li Q, Dong L, Zhu Y, Bai T, Wang S, Hao P, Yang W, Zhang Y, Han J, Yu H, Li D, Gao GF, Wu G, Wang Y, Yuan Z, Shu Y. 2013. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med 368:1888-1897. http://dx.doi.org/10.1056/NEJMoa1304459.
3. Uyeki TM. 2009. Human infection with highly pathogenic avian influenza A (H5N1) virus: review of clinical issues. Clin Infect Dis 49:279-290. http://dx.doi.org/10.1086/600035.
4. Zambon M. 2014. Developments in the treatment of severe influenza: lessons from the pandemic of 2009 and new prospects for therapy. Curr Opin Infect Dis 27:560-565. http://dx.doi.org/10.1097/QCO.0000000000000113.
5. Chan PK, Lee N, Zaman M, Adisasmito W, Coker R, Hanshaoworakul W, Gasimov V, Oner AF, Dogan N, Tsang O, Phommasack B, Touch S, Bamgboye E, Swenson A, Toovey S, Dreyer NA. 2012. Determinants of antiviral effectiveness in influenza virus A subtype H5N1. J Infect Dis 206:1359-1366. http://dx.doi.org/10.1093/infdis/jis509.
6. Hu Y, Lu S, Song Z, Wang W, Hao P, Li J, Zhang X, Yen HL, Shi B, Li T, Guan W, Xu L, Liu Y, Wang S, Zhang X, Tian D, Zhu Z, He J, Huang K, Chen H, Zheng L, Li X, Ping J, Kang B, Xi X, Zha L, Li Y, Zhang Z, Peiris M, Yuan Z. 2013. Association between adverse clinical outcome in human disease caused by novel influenzaAH7N9virus and sustained viral shedding and emergence of antiviral resistance. Lancet 381:2273-2279. http://dx.doi.org/10.1016/S0140-6736 (13) 61125-3.
7. de Jong MD, Tran TT, Truong HK, Vo MH, Smith GJ, Nguyen VC, Bach VC, Phan TQ, Do QH, Guan Y, Peiris JS, Tran TH, Farrar J. 2005. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 353:2667-2672. http://dx.doi.org/10.1056/NEJMoa054512.
8. Shriver Z, Trevejo JM, Sasisekharan R. 2015. Antibody-based strategies to prevent and treat influenza. Front Immunol 6:315. http://dx.doi.org/10.3389/fimmu.2015.00315.
9. Hung IF, To KK, Lee CK, Lee KL, Chan K, Yan WW, Liu R, Watt CL, Chan WM, Lai KY, Koo CK, Buckley T, Chow FL, Wong KK, Chan HS, Ching CK, Tang BS, Lau CC, Li IW, Liu SH, Chan KH, Lin CK, Yuen KY. 2011. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis 52:447-456. http://dx.doi.org/10.1093/cid/ciq106.
10. Luke TC, Kilbane EM, Jackson JL, Hoffman SL. 2006. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med 145:599-609. http://dx.doi.org/10.7326/0003-4819-145-8-200610170-00139.
11. Simmons CP, Bernasconi NL, Suguitan AL, Mills K, Ward JM, Chau NV, Hien TT, Sallusto F, Ha do Q, Farrar J, de Jong MD, Lanzavecchia A, Subbarao K. 2007. Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Med 4:e178. http://dx.doi.org/10.1371/journal.pmed.0040178.
12. Krammer F, Palese P. 2013. Influenza virus hemagglutinin stalk-based antibodies and vaccines. Curr Opin Virol 3:521-530. http://dx.doi.org/10.1016/j.coviro.2013.07.007.
13. Viswanathan K, Shriver Z, Babcock GJ. 2015. Amino acid interaction networks provide a new lens for therapeutic antibody discovery and antiviral drug optimization. Curr Opin Virol 11:122-129. http://dx.doi.org/10.1016/j.coviro.2015.03.019.
14. Tharakaraman K, Subramanian V, Viswanathan K, Sloan S, Yen HL, Barnard DL, Leung YH, Szretter KJ, Koch TJ, Delaney JC, Babcock GJ, Wogan GN, Sasisekharan R, Shriver Z. 2015. A broadly neutralizing human monoclonal antibody is effective against H7N9. Proc Natl Acad Sci U S A 112:10890-10895. http://dx.doi.org/10.1073/pnas.1502374112.
15. Kuiken T, Taubenberger JK. 2008. Pathology of human influenza revisited. Vaccine 26(Suppl 4):D59-D66.
16. Short KR, Kroeze EJ, Fouchier RA, Kuiken T. 2014. Pathogenesis of influenza-induced acute respiratory distress syndrome. Lancet Infect Dis 14:57-69. http://dx.doi.org/10.1016/S1473-3099 (13) 70286-X.
17. Chen W, Janz DR, Shaver CM, Bernard GR, Bastarache JA, Ware LB. 2015. Clinical characteristics and outcomes are similar in ARDS diagnosed by oxygen saturation/FiO2 ratio compared with PaO2/FiO2 ratio. Chest 148:1477-1483. http://dx.doi.org/10.1378/chest.15-0169.
18. ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporota L, Slutsky AS. 2012. Acute respiratory distress syndrome: the Berlin Definition. JAMA 307:2526-2533.
19. Matute-Bello G, Downey G, Moore BB, Groshong SD, Matthay MA, Slutsky AS, Kuebler WM. Acute Lung Injury in Animals Study Group 2011. An official American Thoracic Society workshop report: features and measurements of experimental acute lung injury in animals. Am J Respir Cell Mol Biol 44:725-738. http://dx.doi.org/10.1165/rcmb.2009-0210ST.
20. Boon AC, deBeauchamp J, Hollmann A, Luke J, Kotb M, Rowe S, Finkelstein D, Neale G, Lu L, Williams RW, Webby RJ. 2009. Host genetic variation affects resistance to infection with a highly pathogenic H5N1 influenzaAvirus in mice. J Virol 83:10417-10426. http://dx.doi.org/10.1128/JVI.00514-09.
21. Srivastava B, Blazejewska P, Hessmann M, Bruder D, Geffers R, Mauel S, Gruber AD, Schughart K. 2009. Host genetic background strongly influences the response to influenza a virus infections. PLoS One 4:e4857. http://dx.doi.org/10.1371/journal.pone.0004857.
22. Siegers JY, Short KR, Leijten LM, de Graaf M, Spronken MI, Schrauwen EJ, Marshall N, Lowen AC, Gabriel G, Osterhaus AD, Kuiken T, van Riel D. 2014. Novel avian-origin influenza A (H7N9) virus attachment to the respiratory tract of five animal models. J Virol 88:4595-4599. http://dx.doi.org/10.1128/JVI.03190-13.
23. Zaraket H, Baranovich T, Kaplan BS, Carter R, Song MS, Paulson JC, Rehg JE, Bahl J, Crumpton JC, Seiler J, Edmonson M, Wu G, Karlsson E, Fabrizio T, Zhu H, Guan Y, Husain M, Schultz-Cherry S, Krauss S, McBride R, Webster RG, Govorkova EA, Zhang J, Russell CJ, Webby RJ. 2015. Mammalian adaptation of influenza A (H7N9) virus is limited by a narrow genetic bottleneck. Nat Commun 6:6553. http://dx.doi.org/10.1038/ncomms7553.
24. Brownstein DG, Gras L. 1997. Differential pathogenesis of lethal mousepox in congenic DBA/2 mice implicates natural killer cell receptor NKR-P1 in necrotizing hepatitis and the fifth component of complement in recruitment of circulating leukocytes to spleen. Am J Pathol 150:1407-1420.
25. Baranovich T, Burnham AJ, Marathe BM, Armstrong J, Guan Y, Shu Y, Peiris JM, Webby RJ, Webster RG, Govorkova EA. 2014. The neuraminidase inhibitor oseltamivir is effective against A/Anhui/1/2013 (H7N9) influenza virus in a mouse model of acute respiratory distress syndrome. J Infect Dis 209:1343-1353. http://dx.doi.org/10.1093/infdis/jit554.
26. Boon AC, deBeauchamp J, Krauss S, Rubrum A, Webb AD, Webster RG, McElhaney J, Webby RJ. 2010. Cross-reactive neutralizing antibodies directed against pandemic H1N1 2009 virus are protective in a highly sensitive DBA/2 mouse influenza model. J Virol 84:7662-7667. http://dx.doi.org/10.1128/JVI.02444-09.
27. Pica N, Iyer A, Ramos I, Bouvier NM, Fernandez-Sesma A, Garcia-Sastre A, Lowen AC, Palese P, Steel J. 2011. The DBA.2 mouse is susceptible to disease following infection with a broad, but limited, range of influenza A and B viruses. J Virol 85:12825-12829. http://dx.doi.org/10.1128/JVI.05930-11.
28. Meliopoulos VA, Karlsson EA, Kercher L, Cline T, Freiden P, Duan S, Vogel P, Webby RJ, Guan Y, Peiris M, Thomas PG, Schultz-Cherry S. 2014. Human H7N9 and H5N1 influenza viruses differ in induction of cytokines and tissue tropism. J Virol 88:12982-12991. http://dx.doi.org/10.1128/JVI.01571-14.
29. Reed L, Muench H. 1938. A simple method of estimating fifty per cent endpoints. Am J Epidemiol 27:493-497.
30. Hooper KA, Bloom JD. 2013. A mutant influenza virus that uses an N1 neuraminidase as the receptor-binding protein. J Virol 87:12531-12540. http://dx.doi.org/10.1128/JVI.01889-13.
31. Govorkova EA, Baranovich T, Seiler P, Armstrong J, Burnham A, Guan Y, Peiris M, Webby RJ, Webster RG. 2013. Antiviral resistance among highly pathogenic influenza A (H5N1) viruses isolated worldwide in 2002-2012 shows need for continued monitoring. Antiviral Res 98:297-304. http://dx.doi.org/10.1016/j.antiviral.2013.02.013.
32. Sleeman K, Guo Z, Barnes J, Shaw M, Stevens J, Gubareva LV. 2013. R292K substitution and drug susceptibility of influenza A (H7N9) viruses. Emerg Infect Dis 19:1521-1524. http://dx.doi.org/10.3201/eid1909.130724.
33. Baluk P, Thurston G, Murphy TJ, Bunnett NW, McDonald DM. 1999. Neurogenic plasma leakage in mouse airways. Br J Pharmacol 126:522-528. http://dx.doi.org/10.1038/sj.bjp. 0702323.
34. Lanari M, Vandini S, Arcuri S, Galletti S, Faldella G. 2013. The use of humanized monoclonal antibodies for the prevention of respiratory syncytial virus infection. Clin Dev Immunol 2013:359683. http://dx.doi.org/10.1155/2013/359683.
35. Marasco WA, Sui J. 2007. The growth and potential of human antiviral monoclonal antibody therapeutics. Nat Biotechnol 25:1421-1434. http://dx.doi.org/10.1038/nbt1363.
36. Corti D, Voss J, Gamblin SJ, Codoni G, Macagno A, Jarrossay D, Vachieri SG, Pinna D, Minola A, Vanzetta F, Silacci C, Fernandez-Rodriguez BM, Agatic G, Bianchi S, Giacchetto-Sasselli I, Calder L, Sallusto F, Collins P, Haire LF, Temperton N, Langedijk JP, Skehel JJ, Lanzavecchia A. 2011. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333:850-856. http://dx.doi.org/10.1126/science.1205669.
37. Nakamura G, Chai N, Park S, Chiang N, Lin Z, Chiu H, Fong R, Yan D, Kim J, Zhang J, Lee WP, Estevez A, Coons M, Xu M, Lupardus P, Balazs M, Swem LR. 2013. An in vivo human-plasmablast enrichment technique allows rapid identification of therapeutic influenza A antibodies. Cell Host Microbe 14:93-103. http://dx.doi.org/10.1016/j.chom.2013.06.004.
38. Henry Dunand CJ, Leon PE, Kaur K, Tan GS, Zheng NY, Andrews S, Huang M, Qu X, Huang Y, Salgado-Ferrer M, Ho IY, Taylor W, Hai R, Wrammert J, Ahmed R, Garcia-Sastre A, Palese P, Krammer F, Wilson PC. 2015. Preexisting human antibodies neutralize recently emerged H7N9 influenza strains. J Clin Invest 125:1255-1268. http://dx.doi.org/10.1172/JCI74374.
39. Li GM, Chiu C, Wrammert J, McCausland M, Andrews SF, Zheng NY, Lee JH, Huang M, Qu X, Edupuganti S, Mulligan M, Das SR, Yewdell JW, Mehta AK, Wilson PC, Ahmed R. 2012. Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly crossreactive memory B cells. Proc Natl Acad Sci U S A 109:9047-9052. http://dx.doi.org/10.1073/pnas.1118979109.
40. Wu Y, Cho M, Shore D, Song M, Choi J, Jiang T, Deng YQ, Bourgeois M, Almli L, Yang H, Chen LM, Shi Y, Qi J, Li A, Yi KS, Chang M, Bae JS, Lee H, Shin J, Stevens J, Hong S, Qin CF, Gao GF, Chang SJ, Donis RO. 2015. A potent broad-spectrum protective human monoclonal antibody crosslinking two haemagglutinin monomers of influenza A virus. Nat Commun 6:7708. http://dx.doi.org/10.1038/ncomms8708.
41. Tsunetsugu-Yokota Y, Ohnishi K, Takemori T. 2006. Severe acute respiratory syndrome (SARS) coronavirus: application of monoclonal antibodies and development of an effective vaccine. Rev Med Virol 16:117-131. http://dx.doi.org/10.1002/rmv. 492.
42. Bossart KN, Zhu Z, Middleton D, Klippel J, Crameri G, Bingham J, McEachern JA, Green D, Hancock TJ, Chan YP, Hickey AC, Dimitrov DS, Wang LF, Broder CC. 2009. A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute Nipah virus infection. PLoS Pathog 5:e1000642. http://dx.doi.org/10.1371/journal.ppat.1000642.
43. Zhu Z, Dimitrov AS, Bossart KN, Crameri G, Bishop KA, Choudhry V, Mungall BA, Feng YR, Choudhary A, Zhang MY, Feng Y, Wang LF, Xiao X, Eaton BT, Broder CC, Dimitrov DS. 2006. Potent neutralization of Hendra and Nipah viruses by human monoclonal antibodies. J Virol 80:891-899. http://dx.doi.org/10.1128/JVI.80.2.891-899.2006.
44. Dreyfus C, Laursen NS, Kwaks T, Zuijdgeest D, Khayat R, Ekiert DC, Lee JH, Metlagel Z, Bujny MV, Jongeneelen M, van der Vlugt R, Lamrani M, Korse HJ, Geelen E, Sahin O, Sieuwerts M, Brakenhoff JP, Vogels R, Li OT, Poon LL, Peiris M, Koudstaal W, Ward AB, Wilson IA, Goudsmit J, Friesen RH. 2012. Highly conserved protective epitopes on influenza B viruses. Science 337:1343-1348. http://dx.doi.org/10.1126/science.1222908.
45. Govorkova EA, Ilyushina NA, McClaren JL, Naipospos TS, Douangngeun B, Webster RG. 2009. Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. Antimicrob Agents Chemother 53:3088-3096. http://dx.doi.org/10.1128/AAC.01667-08.
46. Chen Z, Wang J, Bao L, Guo L, Zhang W, Xue Y, Zhou H, Xiao Y, Wang J, Wu F, Deng Y, Qin C, Jin Q. 2015. Human monoclonal antibodies targeting the haemagglutinin glycoprotein can neutralize H7N9 influenza virus. Nat Commun 6:6714. http://dx.doi.org/10.1038/ncomms7714.
47. Earn DJD, Dushoff J, Levin SA. 2002. Ecology and evolution of the flu. Trends Ecol Evol 17:334-340. http://dx.doi.org/10.1016/S0169-5347 (02) 02502-8.
48. Thyagarajan B, Bloom JD. 2014. The inherent mutational tolerance and antigenic evolvability of influenza hemagglutinin. Elife 3: http://dx.doi.org/10.7554/eLife.03300.
49. Wu NC, Young AP, Al-Mawsawi LQ, Olson CA, Feng J, Qi H, Chen SH, Lu IH, Lin CY, Chin RG, Luan HH, Nguyen N, Nelson SF, Li X, Wu TT, Sun R. 2014. High-throughput profiling of influenza A virus hemagglutinin gene at single-nucleotide resolution. Sci Rep 4:4942. http://dx.doi.org/10.1038/srep04942.
50. Brandenburg B, Koudstaal W, Goudsmit J, Klaren V, Tang C, Bujny MV, Korse HJ, Kwaks T, Otterstrom JJ, Juraszek J, van Oijen AM, Vogels R, Friesen RH. 2013. Mechanisms of hemagglutinin targeted influenza virus neutralization. PLoS One 8:e80034. http://dx.doi.org/10.1371/journal.pone.0080034.
51. Terajima M, Cruz J, Co MD, Lee JH, Kaur K, Wrammert J, Wilson PC, Ennis FA. 2011. Complement-dependent lysis of influenza a virusinfected cells by broadly cross-reactive human monoclonal antibodies. J Virol 85:13463-13467. http://dx.doi.org/10.1128/JVI.05193-11.